Patents Assigned to Xynomic Pharmaceuticals, Inc.
  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11753409
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 12, 2023
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11306086
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 19, 2022
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf